DERM Dermira Inc.

+0.19  (+1%)
Previous Close 12.99
Open 13.15
Price To Book -62.76
Market Cap 557885241
Shares 42,328,167
Volume 733,464
Short Ratio
Av. Daily Volume 2,209,226

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 5, 2018 - failed to meet all co-primary endpoints.
Olumacostat glasaretil (DRM01)
Approval announced June 29, 2018.
Glycopyrronium tosylate
Primary axillary hyperhidrosis
Phase 2b data released March 18, 2019 met primary endpoints. Phase 3 trial to be initiated later in 2019.
Atopic Dermatitis
Proof of concept initiation announced February 22, 2019 with data due 2H 2019.
QBREXZA (glycopyrronium)
Primary palmar hyperhidrosis

Latest News

  1. Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth
  2. Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  3. Dermira (DERM) Catches Eye: Stock Jumps 12%
  4. Dermira Prices $130.0 Million Public Offering of Common Stock
  5. Why Dermira Stock Jumped Again Today
  6. Company News For Mar 19, 2019
  7. See what the IHS Markit Score report has to say about Dermira Inc.
  8. Can Dermira Stock Keep Soaring?
  9. Edited Transcript of DERM earnings conference call or presentation 26-Feb-19 9:30pm GMT
  10. Dermira Announces Proposed Public Offering of Common Stock
  11. Why Dermira Stock Is Soaring More than 80% Today
  12. Stocks making the biggest moves midday: Facebook, Deutsche Bank, Lumber Liquidators & more
  13. Dermira News: Why DERM Stock Is Skyrocketing Today
  14. Why Dermira's Shares Are Doubling Today
  15. Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop
  16. Dermira Shares Rocket After Successful Phase II Eczema Treatment Study
  17. Why Dermira Shares Are Shooting Higher After Last Year's Disappointment
  18. Dermira shares soar 83% premarket on news of positive trial of dermatitis treatment
  19. Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis